Vanguard Personalized Indexing Management LLC Has $282,000 Position in Core Laboratories Inc. (NYSE:CLB)

Vanguard Personalized Indexing Management LLC lifted its holdings in Core Laboratories Inc. (NYSE:CLB) by 15.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,907 shares of the oil and gas company’s stock after buying an additional 1,907 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Core Laboratories were worth $282,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Headlands Technologies LLC bought a new position in shares of Core Laboratories in the second quarter worth about $36,000. GAMMA Investing LLC raised its position in Core Laboratories by 31.6% in the 1st quarter. GAMMA Investing LLC now owns 3,570 shares of the oil and gas company’s stock worth $61,000 after purchasing an additional 857 shares during the last quarter. CWM LLC lifted its holdings in Core Laboratories by 1,178.6% during the 1st quarter. CWM LLC now owns 3,580 shares of the oil and gas company’s stock worth $61,000 after buying an additional 3,300 shares in the last quarter. Lindbrook Capital LLC boosted its position in Core Laboratories by 19.7% in the 1st quarter. Lindbrook Capital LLC now owns 3,713 shares of the oil and gas company’s stock valued at $63,000 after buying an additional 612 shares during the last quarter. Finally, Platinum Investment Management Ltd. increased its stake in shares of Core Laboratories by 43.8% in the 4th quarter. Platinum Investment Management Ltd. now owns 5,577 shares of the oil and gas company’s stock valued at $98,000 after buying an additional 1,698 shares during the period. Institutional investors and hedge funds own 97.81% of the company’s stock.

Core Laboratories Stock Performance

Shares of NYSE:CLB opened at $18.27 on Monday. The firm’s 50 day simple moving average is $19.65 and its 200 day simple moving average is $18.72. Core Laboratories Inc. has a fifty-two week low of $13.82 and a fifty-two week high of $25.20. The company has a market capitalization of $856.86 million, a price-to-earnings ratio of 20.76, a P/E/G ratio of 1.09 and a beta of 2.37. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.39 and a quick ratio of 1.68.

Core Laboratories (NYSE:CLB) last posted its earnings results on Wednesday, July 24th. The oil and gas company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.01. Core Laboratories had a net margin of 5.44% and a return on equity of 15.20%. The company had revenue of $130.58 million for the quarter, compared to analyst estimates of $132.85 million. During the same period last year, the business posted $0.23 earnings per share. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Core Laboratories Inc. will post 0.8 earnings per share for the current year.

Core Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Monday, August 5th were issued a dividend of $0.01 per share. The ex-dividend date was Monday, August 5th. This represents a $0.04 annualized dividend and a yield of 0.22%. Core Laboratories’s dividend payout ratio is presently 4.55%.

Analyst Ratings Changes

Several equities analysts recently issued reports on CLB shares. Stifel Nicolaus raised their price target on Core Laboratories from $18.00 to $22.00 and gave the company a “hold” rating in a report on Friday, July 26th. StockNews.com cut shares of Core Laboratories from a “hold” rating to a “sell” rating in a research report on Tuesday, September 17th. Bank of America cut their price objective on shares of Core Laboratories from $16.00 to $15.00 and set an “underperform” rating on the stock in a report on Monday, July 15th. Finally, Piper Sandler lowered their target price on shares of Core Laboratories from $18.00 to $17.00 and set a “neutral” rating for the company in a report on Monday, July 15th. Two analysts have rated the stock with a sell rating and two have assigned a hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $18.00.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.